Toll-Interacting Protein Regulates Immune Cell Infiltration and Promotes Colitis-Associated Cancer.

Details

Ressource 1Download: 32114379_BIB_9F4D29F09585.pdf (34882.77 [Ko])
State: Public
Version: author
License: CC BY-NC-ND 4.0
Serval ID
serval:BIB_9F4D29F09585
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Toll-Interacting Protein Regulates Immune Cell Infiltration and Promotes Colitis-Associated Cancer.
Journal
iScience
Author(s)
Begka C., Pattaroni C., Mooser C., Nancey S., McCoy K.D., Velin D., Maillard M.H.
Working group(s)
Swiss IBD Cohort Study Group
ISSN
2589-0042 (Electronic)
ISSN-L
2589-0042
Publication state
Published
Issued date
08/02/2020
Peer-reviewed
Oui
Volume
23
Number
3
Pages
100891
Language
english
Notes
Publication types: Journal Article
Publication Status: aheadofprint
Abstract
Expression of Toll-interacting protein (Tollip), a potent TLR modulator, decreases in patients with inflammatory bowel diseases (IBD), whereas Tollip <sup>-/-</sup> mice are susceptible to colitis. Tollip expression was shown to be reduced in sporadic adenoma . In contrast, we found variable Tollip expression in patients with colitis-associated adenomas. In Tollip <sup>-/-</sup> mice challenged to develop colitis-associated cancer (CAC), tumor formation was significantly reduced owing to decreased mucosal proliferative and apoptotic indexes. This protection was associated with blunt inflammatory responses without significant changes in microbial composition. mRNA expression of Cd62l and Ccr5 homing receptors was reduced in colons of untreated Tollip <sup>-/-</sup> mice, whereas CD62L <sup>+</sup> CD8 <sup>+</sup> T cells accumulated in the periphery. In Tollip-deficient adenomas Ctla-4 mRNA expression and tumor-infiltrating CD4 <sup>+</sup> Foxp3 <sup>+</sup> regulatory T cell (Treg) were decreased. Our data show that protection from CAC in Tollip-deficient mice is associated with defects in lymphocyte accumulation and composition in colitis-associated adenomas.
Keywords
Biological Sciences, Cancer, Immunology
Pubmed
Open Access
Yes
Create date
05/03/2020 16:37
Last modification date
12/01/2022 8:12
Usage data